Exelixis Q3 revenue $539.5M, EPS $0.40; raises FY 2024 guidance

EXELIXIS, INC.

2024-Q3 EPS reported $1.28 revenue$1,601,946,000

Q3 net product revenue $478.1M (cabozantinib franchise) vs $426.5M YoY, +12%.
GAAP diluted EPS $0.40, non-GAAP diluted EPS $0.47; prior year $0.00 and $0.10.
Raises 2024 total revenue and net product revenue guidance on strong commercial performance.
Favorable U.S. District Court ruling on cabozantinib patent litigation received.
New collaboration with Merck adds two phase 3 trials for zanzalintinib in renal cell carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.